Navigation Links
DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
Date:4/10/2013

tudies in various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer.

Based on published research, the mechanism of action of VAL-083 is understood to be a bi-functional alkylating agent; however, the functional groups associated with alkylating events has been shown to differ from other alkylating agents used in the treatment of GBM.

VAL-083 has previously demonstrated activity in cyclophosphamide, BCNU and phenylanine mustard resistant cell lines and no evidence of cross-resistance has been encountered in published clinical studies.  Based on the presumed alkylating functionality of VAL-083, published literature suggests that DNA repair mechanisms associated with Temodar and nitrosourea resistance, such as 06-methylguanine methyltransferase (MGMT), may not confer resistance to VAL-083. 

VAL-083 readily crosses the blood brain barrier where it maintains a long half-life in comparison to the plasma.  Published preclinical and clinical research demonstrates that VAL-083 is selective for brain tumor tissue.

VAL-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors.  In general, tumor regression was achieved following therapy in greater than 40 percent of patients treated and stabilization was achieved in an additional 20 to 30 percent.  In published clinical studies, VAL-083 has previously been shown to have a statistically significant impact on median survival in high-grade gliomas when combined with radiation versus radiation alone. 

The main dose-limiting toxicity related to the administration of VAL-083 in previous clinical studies was myelosuppres
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
2. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
3. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
4. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
5. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
6. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
7. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
8. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
9. Global Pharmacy Automation Market 2012-2016 with McKesson Corp., ScriptPro LLC, Parata Systems LLC Dominating
10. Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite to Achieve e-Pedigree Compliance
11. Zosano Pharma, Inc. Announces Key Strategic Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014  A substantial ... make decisions about which therapies are included in ... placement, according to a new Manhattan Research study, ... . The study finds that P&T committee members ... benefits managers (PBMs) have set a high bar ...
(Date:7/31/2014)... SAN FRANCISCO , July 31, 2014 /PRNewswire/ ... ) and Aspira Scientific ( Milpitas, California ... joint venture to develop and commercialize new fluorination ... biologically active molecules has benefited from the use ... metabolism, and combine lipophilicity with polarity to improve ...
(Date:7/31/2014)... Ariz. , July 31, 2014 For ... public can watch the implantation of the SynCardia temporary ... paper and matching video posted on the Journal of ... video and read the paper on the SynCardia Total ... The 16-minute video accompanies "Implantation of the SynCardia Total ...
Breaking Medicine Technology:Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 2Formulary Decision Makers Say Pharma-Provided Patient Support Solutions Influence Formulary Placement 3Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3
... Association of Clinical Research Organizations (ACRO), which represents the ... and the public in the U.S. and worldwide, issued ... Implications of the Globalization of Clinical Research" published in ... England Journal of Medicine : The article by ...
... Journal of Medicine employs Quest Diagnostics, blood-based leukemia testingMADISON, ... specimens may detect abnormal white blood cells in patients ... develops, according to research published in the current issue ... Medicine . The finding may lead to a better ...
Cached Medicine Technology:ACRO Comments on NEJM Article on Globalization of Clinical Research 2ACRO Comments on NEJM Article on Globalization of Clinical Research 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 4
(Date:7/31/2014)... Amy Norton HealthDay Reporter ... not have had fast food, TVs or cigarettes, but people ... a new research review speculates on some reasons why. ... the Aleutian Islands and the American Southwest, researchers have found ... from fatty substances that build up, eventually leading to heart ...
(Date:7/31/2014)... Steven Reinberg HealthDay ... Difficulties in civilian life, rather than war experiences, are a ... at home, a new study suggests. Setbacks such as ... returning vets -- may make as many as 13 percent ... to combat-related traumatic events has an important effect on mental ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 (HealthDay ... has shown an increased risk of spreading undetected cancers in ... market. In a letter that was to be sent ... that its laparoscopic power morcellators be returned to the company, ... of new morcellators had been suspended in April after the ...
(Date:7/31/2014)... THURSDAY, July 31, 2014 (HealthDay News) -- Preschoolers with ... who have strong language skills, according to a new ... language growth in children with disabilities, researchers found. On ... if their classmates have weak language skills, they said. ... among children,s language skills at the end of the ...
(Date:7/31/2014)... The International Bottled Water Association (IBWA) today launched a ... “ Bottled Water – Always there when you need it ... water plays in times of natural disasters and other emergencies. ... period for hurricanes and other forms of severe weather, and ... take a moment to re-assess their risks and update hurricane ...
Breaking Medicine News(10 mins):Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 2Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 3Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 3Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 2Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 3Health News:Preschoolers With Special Needs May Gain From 'Inclusion' Classrooms 2Health News:New Video Showcases Bottled Water’s Important Role in Times of Emergencies 2Health News:New Video Showcases Bottled Water’s Important Role in Times of Emergencies 3Health News:New Video Showcases Bottled Water’s Important Role in Times of Emergencies 4
... abnormal brain activity, researchers say , THURSDAY, Feb. 18 ... illness known as generalized anxiety disorder, a new study ... ways. , The study authors say the research ... suffering from debilitating anxiety. , "Patients experience anxiety ...
... ... Centers for Knee and Hip Replacement are part of the Blue Cross and Blue Shield ... ... has designated Abington Memorial Hospital as a Blue Distinction Center for Spine Surgery ...
... ... his new Authentic/Biblica book, Talking Smack , ... (PRWEB) February 18, 2010 -- Are you talking smack? You’d better be., , ... who has worked with parents and teens for more than 20 years and created the ...
... ... to begin an online journey, find the right ways to embrace this new communication environment ... ... of change for communicators everywhere. After a devastating recession in 2009, this year has ...
... ... delivery errors while protecting patients and caregivers. , ... Ferndale, MI (PRWEB) Feb. 18, 2010 ... of the Enovate Medication Cart, the newest addition to its medical cart series. ...
... ... (PCBs) and PCB engineering and design services, announces the availability of specialized PCBs for ... develop medical electronic printed circuit assemblies. , ... Chicago, IL (PRWEB) February 18, 2010 -- Electronic ...
Cached Medicine News:Health News:Anxiety Disorder Patients Process Emotions Differently 2Health News:Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM) 2Health News:Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM) 3Health News:Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM) 4Health News:Talking Smack to Keep Kids Drug-Free 2Health News:Talking Smack to Keep Kids Drug-Free 3Health News:Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters 2Health News:Enovate Announces New Lightweight Medication Cart Series 2Health News:Enovate Announces New Lightweight Medication Cart Series 3Health News:Electronic Interconnect Offers Medical Electronics, PCBs, Design Engineering 2Health News:Electronic Interconnect Offers Medical Electronics, PCBs, Design Engineering 3
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
An indirect immunofluorescence antibody test for the qualitative and semi-quantitative detection of endomysial antibodies (EMA) in human serum as an aid in the diagnosis of celiac disease and dermati...
Medicine Products: